摘要
目的对幽门螺杆菌(Hp)感染性消化性溃疡患者予以奥美拉唑与雷贝拉唑联用治疗的临床可用性进行评价。方法以"中心随机"的方式,于2015年8月-2019年6月间在该院收治患者当中随机选取所收治的200例Hp感染性消化性溃疡患者,分别应用单用雷贝拉唑治疗(对照组,100例)和加以奥美拉唑联用治疗(观察组,100例),同时观察两组结果(治疗前后症状积分、腹痛消失时间、消化性溃疡愈合率与有效率、Hp清除率、不良反应率)。结果观察组治疗后症状积分(55.19±2.03)分高于对照组,差异有统计学意义(t=7.550,P<0.05);同时两组组间比较,差异有统计学意义(t=26.997、26.160,P<0.05)。观察组消化性胃溃疡与十二指肠溃疡患者的腹痛消失时间(2.94±1.34) min、(1.75±0.95) min短于对照组,差异有统计学意义(t=2.400、3.860,P<0.05)。观察组愈合率(92.00%)和总有效率(97.00%)均高于对照组,差异有统计学意义(χ~2=4.420、4.030,P<0.05)。观察组Hp清除率(96.00%)高于对照组,差异有统计学意义(χ~2=4.350,P<0.05)。但两组不良反应率比较,差异无统计学意义(χ~2=0.340,P>0.05)。结论联合奥美拉唑与雷贝拉唑治疗Hp感染性消化性溃疡患者的疗效确切。
Objective To evaluate the clinical availability of omeprazole combined with rabeprazole in patients with helicobacter pylori(Hp) infectious peptic ulcer. Methods Random select a total of 200 patients with Hp-infected peptic ulcer admitted to the hospital from August 2015 to June 2019 were treated with rabeprazole alone(control group, 100 cases)and omeprazole combined treatment(observation group, 100 cases), while observing the two groups of results(symptom score before and after treatment, disappearance of abdominal pain, peptic ulcer healing rate and effectiveness, Hp clearance rate,adverse reaction rate). Results The symptom scores of the observation group after treatment(55.19±2.03) points were higher than those of the control group(t=7.550, P<0.05). There were statistically significant differences between the two groups(t=26.997, 26.160, P<0.05). The disappearance time of abdominal pain(2.94 ±1.34) min,(1.75 ±0.95)min in patients with digestive gastric ulcer and duodenal ulcer was shorter than that of the control group,the difference was statistically significant(t=2.400, 3.860, P<0.05). The healing rate(92.00%) and total effective rate(97.00%) of the observation group were higher than those of the control group,the difference was statistically significant(χ~2=4.420, 4.03, P <0.05). The Hp clearance rate(96.00%) in the observation group was higher than that in the control group,the difference was statistically significant(χ~2=4.350, P<0.05). However, there was no statistically significant difference in the adverse reaction rates between the two groups(χ~2=0.340, P>0.05). Conclusion The efficacy of combined omeprazole and rabeprazole in the treatment of patients with Hp-infected peptic ulcer is definite.
作者
王建学
WANG Jian-xue(Department of Internal Medicine,Laiwu Iron and Steel Group Lunan Mining Co.,Ltd.Linyi,Shandong Province,276400 China)
出处
《中外医疗》
2020年第6期24-26,共3页
China & Foreign Medical Treatment
